Study objective and method
Results
Changes in SF-36 scores
Stable QoL during treatment with teriflunomide for up to 24 months
Annualized relapse rates
Patient-reported disability rates
Increased marginally
Fatigue scores
Median change +2 points (no substantial change)
Acceptability of oral teriflunomide
Highest median scores of convenience and side effects
TSQM domains mean scores for:
Global satisfaction
Effectiveness
Side
effects
Convenience
Increased nominally from month 6 to 24 side effects (though not significantly)
High treatment adherence
88.2%
at month 24
Healthcare utilization
Decreased during the study period
DMT-naïve patients
Lower mean TSQM scores in all domains (except convenience)
VS
Switch patients
Different treatment expectations and improved outcomes after switching therapy
Conclusion
Teri-LIFE
Real-world study showed consistent:
As seen in routine clinical practice and previous RCT and RW studies
QoL
Efficacy
Safety
Treatment
satisfaction
Health economic
outcomes
In teriflunomide-treated relapsing MS patients
DMT: Disease-modifying therapy; MS: Multiple sclerosis; QoL: Quality of life; RCT: Randomized controlled trial; RW: Real-world; SF-36: Short form-36;
TSQM: Treatment satisfaction questionnaire for medication.this study has not been reviewed by SFDA
MAT-BH-2300590-V1-Oct.2023